Focal One® brings the answer to all requirements for ideal focal therapy: accurate and MR-fused imaging, non-invasive surgical approach, precise and efficient therapeutic energy and treatment validation with post-treatment MRI.
Stereotactic Lithotripsy. "Freeline" ultrasound localization system. A user-friendly system to guarantee the best treatment efficacy. Available on the Sonolith® product range.
EDAP Announces FDA Breakthrough Device Designation for Focal One in the Treatment of Deep Infiltrating Rectal Endometriosis
Read more
EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that it has received reimbursement approval in Switzerland for the use of High-Intensity Focused Ultrasound (HIFU) in the treatment of prostate cancer. This reimbursement took effect on July 1, 2023.
Read more
Meeting to Showcase EDAP’s Focal One® Robotic High Intensity Focused Ultrasound (HIFU) Platform for the Management of Prostate Cancer
Read more
EDAP TMS SA, a global leader in robotic energy-based therapies, today announced that the Company will host a webcast that will feature a live procedure broadcast of its Focal One HIFU as a potential treatment for ablating cancer tissue in patients who are diagnosed with prostate cancer. The webcast is scheduled for Tuesday, April 18th at 12:00 p.m. PDT (3:00 p.m. EDT).
Read more
As an alternative to standard radical therapies such as surgery and radiotherapy, EDAP TMS offers a non-invasive treatment based on High Intensity Focused Ultrasound (HIFU)...
As a world leader in extracorporeal lithotripsy for more than 40 years, EDAP TMS offers a complete range of non-invasive and minimally invasive solutions covering the full scope of Urinary Tract Stone Indications.